Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Completed Phase 1 Interventional Results available

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions
Thrombosomes
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice

NCT01431378
View directory record Official record
Conditions
Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199
View directory record Official record
Conditions
Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Columbus, Ohio • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial

NCT01393704
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Vasopressin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 22, 2026, 4:05 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Hypothermia During Intracranial Aneurysm Surgery Trial

NCT00029133
View directory record Official record
Conditions
Aneurysm, Hypothermia, Subarachnoid Hemorrhage
Interventions
mild intraoperative hypothermia (33 degrees Celsius)
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:05 AM EDT
Completed No phase listed Observational

Identification of Novel Molecular Markers for Vasospasm

NCT02389634
View directory record Official record
Conditions
Cerebral Vasospasm, Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

NCT02472184
View directory record Official record
Conditions
Uterine Fibroids, Vaginal Bleeding
Interventions
Office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-center:The Small (14F) Percutaneous Catheter vs. Large (28-40F) Open Chest Tube for Traumatic Hemothorax (P-CAT)

NCT03546764
View directory record Official record
Conditions
The Efficacy of Percutaneous Catheter vs. Open Chest Tube, Traumatic Hemothorax
Interventions
Percutaneous catheter
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Completed No phase listed Observational

Trauma Induced Coagulopathy and Inflammation

NCT03128658
View directory record Official record
Conditions
Trauma Injury, Trauma, Coagulopathy
Interventions
Thromboelastography, Computational model
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

PF-06741086 Multiple Dose Study in Severe Hemophilia

NCT02974855
View directory record Official record
Conditions
Hemophilia A or B
Interventions
PF-06741086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 22, 2026, 4:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Not listed No phase listed Observational

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601
View directory record Official record
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine in Treating Patients With Myelofibrosis

NCT00381693
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
azacitidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321
View directory record Official record
Conditions
Hemophilia A or B
Interventions
PF-06741086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

NCT00245648
View directory record Official record
Conditions
Myocardial Infarction
Interventions
fibrinolytic therapy or combination reduced fibrinolytic therapy
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 22, 2026, 4:05 AM EDT
Recruiting No phase listed Observational

Non-Invasive Monitoring Methods in Patients With Acute Brain Injury

NCT06504238
View directory record Official record
Conditions
Brain Injury, Acute
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated No phase listed Observational

Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)

NCT01585311
View directory record Official record
Conditions
Subarachnoid Hemorrhage (SAH), Tachycardia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

HEROIC (Heparin Requirement in Counterpulsation)

NCT00445211
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Heparin, Without Heparin
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 22, 2026, 4:05 AM EDT
Completed No phase listed Observational

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

NCT01830712
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070899
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
116
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 22, 2026, 4:05 AM EDT